Antibiotic Resistance Market Expected To Witness A Substantial Growth Of .48 Billion By 2030: Grand View Research IncPosted by Mrudula Karmarkar on June 25th, 2024 San Francisco, 25 June 2024: The ReportAntibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 The global antibiotic resistance market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period. The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies. Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset. The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections. For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level. However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered “innovative” enough to be capable of overcoming antibiotic resistance as defined by WHO. Request sample report of Antibiotic Resistance Market@https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market/request/rs1 According to the Pew Charitable Trusts article published in July 2023, antibiotic-resistant bacteria represent a rising danger to public health. Annually, more than 2.8 million infections in the U.S. are resistant to antibiotics, leading to over 35,000 deaths. Moreover, increasing need for new antibiotic therapies and rising public health concerns and awareness are expected to drive market growth in the forecast period. Antibiotic Resistance Market Report Highlights
Growing need for new antibiotic therapies to address antibiotic resistance is boosting the demand for the global market. According to the Science Daily article published in July 2023, The World Health Organization has identified antibiotic-resistant bacteria as a major global health threat. A recent discovery by Adela Melcrova, a biophysicist at the University of Groningen in the Netherlands, reveals that the relatively new antibiotic AMC-109 works by disrupting the organization of bacterial cell membranes. This unique mechanism sets AMC-109 apart from most other antibiotics and holds promise for opening new avenues in future treatments and drug development. Antimicrobial resistance (AMR) poses a significant threat to the global economy, impacting international trade, healthcare costs, and productivity. According to WHO article published in May 2023,WHO, in partnership with the Global AMR R&D Hub, presented a report to G7 Finance and Health Ministers. The report details progress in encouraging the development of new antibacterial treatments. The Global AMR R&D Hub, a collaborative effort involving countries and organizations, adopts a One Health approach to enhance coordination in global AMR R&D. This collaborative effort is significantly growing the demand for the market. Antibiotic Resistance Market Report Scope
The worldwide increase in antibiotic resistance is a major threat, weakening the effectiveness of common antibiotics against widespread bacterial infections. According to the WHO article published in November 2023, the Global Antimicrobial Resistance and Use Surveillance System (GLASS) report highlights resistance rates observed in prevalent bacterial pathogens. Moreover, the report reveals median rates of 42% for third-generation cephalosporin-resistant E. coli and 35% for methicillin-resistant Staphylococcus aureus in 76 countries. Of significant concern is the finding that 1 in 5 cases of urinary tract infections caused by E. coli exhibited reduced susceptibility to standard antibiotics like ampicillin, co-trimoxazole, and fluoroquinolones in 2020. This is making it increasingly difficult to effectively treat common infections, intensifying the rising public health concern and awareness surrounding antibiotic resistance in the market. Partnerships and collaborations for the new treatment methods are boosting the demand for the market. According to Karolinska Institutet, in November 2023, the Federico Iovino group at Karolinska Institutet initiated a dynamic collaboration with Therakind to discover innate molecules with antimicrobial power, specifically targeting antibiotic-resistant bacterial infections, especially those affecting the brain. This innovative partnership arises from the recognition of the limited effectiveness of current antibiotics in crossing the protective blood-brain barrier. Focusing on unique molecules within bodies, this collaboration seeks to revolutionize treatments for infections that have become resistant to traditional antibiotics, particularly those challenging brain infections. List of Key Players in the Antibiotic Resistance Market
Like it? Share it! More by this author |